New York’s Bristol-Myers Squibb is increasing its offer to purchase ImClone Systems to $4.7 billion dollars. The takeover bid has turned hostile, as BMS intends to take their offer directly to shareholders. ImClone, the 24-year-old biopharmaceutical company, turned down BMS’s previous bid of $60...
(less)
Imclone’s Sole Product, Erbitux, Failed to Slow Tumor Growth in Lung Cancer; Marriott International 2Q Earnings Beat Analyst Estimates; Intel 2Q Sales, Profit Estimates Raised at Banc of America
(less)
You are Watching: BMS and ImClone Deal Review, with Mike King. Why is BMS after ImClone, and what will happen next? Carl Icahns says the $60 bid is too low. Mike King believes Icahn is waiting for the Genentech Roche transaction to play out, in order to see the valuation metrics that will be us...
(less)
According to Wall Street Journal, Eli Lilly May Buy ImClone, Though ImClone’s Largest Shareholder Carl Icahn Will Not Reveal Which Company is Trying to Outbid Bristol-Myers Squibb; Bidding for ImClone is Pipeline Play
(less)
Icahn Rejects $60/share Bid; Meanwhile, New Suitor Remains Unknown - After Several Conversations, Undisclosed Pharmaceutical Company Bidding $70/share for ImClone
(less)
Safe Search Filter is ON. Truveo understands that some content may not be appropriate for all users. We provide a Safe Search Filter so that you can choose the content best suited to your personal interest. Turning OFF the Safe Search Filter may display content that is only suitable for viewers over 18 years of age. Click the button below if you are over 18 and would like to turn OFF the Safe Search Filter.